Heron Therapeutics Launches Aponvie for the Management of Postoperative Nausea and Vomiting in the US
Shots:
- The company reported the commercial availability of Aponvie, a ready-to-use, easy-to-administer, innovative IV formulation for the prevention of PONV in adults
- The results showed that the patients treated with aprepitant resulted in ~50% fewer patients vomiting in the first 24 and 48hrs. over ondansetron (IV). Additionally, Aponvie (32mg) was found to be bioequivalent to oral aprepitant (40mg) with the rapid achievement of therapeutic drug levels in the P-I study
- Aponvie is an injectable emulsion formulation of aprepitant, a substance P/neurokinin-1 (NK1) receptor antagonist. The formulation is identical to Heron’s Cinvanti which is indicated for chemotherapy-induced nausea and vomiting
Ref: PR Newswire | Image: Heron
Related Post:- Heron Therapeutics’ Aponvie (HTX-019) Receives the US FDA’s Approval for the Prevention of Postoperative Nausea and Vomiting
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
